Kwan Justin, Pua Uei
Department of Vascular and Interventional Radiology, Tan Tock Seng Hospital, Singapore 388403, Singapore.
Cancers (Basel). 2021 Mar 18;13(6):1371. doi: 10.3390/cancers13061371.
The liver is frequently the most common site of metastasis in patients with colorectal cancer, occurring in more than 50% of patients. While surgical resection remains the only potential curative option, it is only eligible in 15-20% of patients at presentation. In the past two decades, major advances in modern chemotherapy and personalized biological agents have improved overall survival in patients with unresectable liver metastasis. For patients with dominant liver metastatic disease or limited extrahepatic disease, liver-directed intra-arterial therapies such as hepatic arterial chemotherapy infusion, chemoembolization and radioembolization are treatment strategies which are increasingly being considered to improve local tumor response and to reduce systemic side effects. Currently, these therapies are mostly used in the salvage setting in patients with chemo-refractory disease. However, their use in the first-line setting in conjunction with systemic chemotherapy as well as to a lesser degree, in a neoadjuvant setting, for downstaging to resection have also been investigated. Furthermore, some clinicians have considered these therapies as a temporizing tool for local disease control in patients undergoing a chemotherapy 'holiday' or acting as a bridge in patients between different lines of systemic treatment. This review aims to provide an update on the current evidence regarding liver-directed intra-arterial treatment strategies and to discuss potential trends for the future.
肝脏是结直肠癌患者最常见的转移部位,超过50%的患者会出现肝转移。虽然手术切除仍然是唯一可能治愈的选择,但初诊时只有15% - 20%的患者适合手术。在过去二十年中,现代化疗和个性化生物制剂取得了重大进展,改善了不可切除肝转移患者的总生存期。对于以肝脏转移为主或肝外转移局限的患者,肝动脉化疗灌注、化疗栓塞和放射性栓塞等肝脏靶向动脉内治疗策略越来越多地被考虑用于改善局部肿瘤反应并减少全身副作用。目前,这些治疗主要用于化疗难治性疾病患者的挽救治疗。然而,它们在一线治疗中与全身化疗联合应用的情况,以及在较小程度上用于新辅助治疗以降期至可切除的情况也已得到研究。此外,一些临床医生将这些治疗视为正在接受化疗“假期”患者局部疾病控制的临时手段,或作为不同线全身治疗之间患者的桥梁。本综述旨在提供有关肝脏靶向动脉内治疗策略的当前证据更新,并讨论未来的潜在趋势。